KRAS variants and ACSL4 co-expression in TCGA colorectal tumours: an abstract-only transcriptomic analysis
In TCGA colorectal tumour data, ACSL4 levels stayed similar across KRAS variant groups, but its co-expression links to senescence and lipid-peroxidation markers fell stepwise from wild-type to G13D. The authors call this a correlational 'orphan state' and say functional validation is needed. [1]
Automatic summary · not editorially reviewed
The key findings
The analysis used TCGA-COAD primary tumours stratified by KRAS codon variant, from wild-type (n = 276) to G13D (n = 30). [1]
ACSL4 expression was preserved across KRAS groups, but its co-expression edge count fell from 8 in wild-type to 0 in G13D. [1]
The authors state that all conclusions are correlational and require functional validation. [1]
The source at a glance
- Study type / format
- Transcriptomic co-expression analysis of existing tumour cohort data (abstract)
- Population / context
- Primary colorectal tumours (TCGA-COAD) grouped by KRAS codon variant: wild-type n = 276, G12D n = 53, G12V n = 38, G13D n = 30.
- Summary based on
- Study abstract
- Publication status
- Preprint · peer-review status not confirmed
- Original publication
- October 12, 2026
TCGA colorectal tumours grouped by KRAS codon variant
The authors asked whether KRAS mutations disrupt an ACSL4-centred programme called ferro-aging, described as an ACSL4-mediated chronic lipid peroxidation programme driving cellular senescence and systemic aging, recently established in primates. They used TCGA-COAD primary tumours, split by KRAS codon variant: wild-type (n = 276), G12D (n = 53), G12V (n = 38) and G13D (n = 30). A 22-gene ferroptosis/NRF2 panel was combined with senescence markers. The authors note that whether KRAS mutations disrupt this axis as an oncogenic escape mechanism had not been examined.
Supporting source [1]
Three computed scores and Spearman co-expression testing
Three metrics were computed: an ACSL4 Orphan State Score, a composite Senescence Score and a lipid-peroxidation proxy correlation. ACSL4 co-expression with senescence markers and with lipid-peroxidation effectors (PTGS2, ALOX5, LPCAT3) was assessed by Spearman correlation with Benjamini–Hochberg correction. This is a transcriptomic, correlational analysis of existing tumour data; the abstract reports no experiments in cells or animals and no follow-up of patients.
Supporting source [1]
Stable ACSL4 levels but fewer co-expression links by variant
ACSL4 expression was preserved across groups (log₂TPM 4.42–4.82; all p > 0.10), but its co-expression edge count fell progressively: 8 in wild-type, 3 in G12D, 1 in G12V and 0 in G13D. The Orphan State Score rose from 0.57 to 8.85 in G13D. In wild-type tumours, ACSL4 significantly co-expressed with its lipid-peroxidation effectors (r = + 0.421). The authors conclude that KRAS mutations progressively sever ACSL4 from both networks, producing an orphan state in which the enzyme is expressed but co-regulatorily decoupled. They state all conclusions are correlational and require functional validation. They also raise, as a consideration, that vitamin C, described as a direct ACSL4 inhibitor in the ferro-aging context, may have unpredictable effects in KRAS-mutant colorectal cancer; this is not a finding of the analysis.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. The work is a correlational transcriptomic analysis of existing TCGA tumour data, with no functional experiments or patient follow-up reported. The vitamin C remark is a consideration, not a tested result.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.